• SoundHound AI previously announced the expansion of “Emily,” MUSC Health’s AI agent built on its agentic AI platform, to cover retail and specialty pharmacy operations, after already supporting more than 2,200,000 patient calls across the health system since 2024.
• This rollout, which is among the first agentic voice implementations integrated with Epic for pharmacy workflows, highlights SoundHound’s growing role in enabling self-service, natural-language access to healthcare services while easing administrative workloads.
• Next, we’ll examine how this Epic-integrated pharmacy expansion for Emily could influence SoundHound AI’s broader enterprise agentic AI investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

SoundHound AI Investment Narrative Recap

To own SoundHound AI, you need to believe its agentic AI platform can win meaningful enterprise adoption across sectors while eventually narrowing substantial losses. The MUSC Health “Emily” pharmacy expansion reinforces the healthcare use case and may support the key near term catalyst of converting more pilots into scaled deployments, but it does not directly resolve the central risk around high operating costs and the company’s path toward sustainable profitability.

Among recent announcements, the launch of OASYS in May 2026 looks especially relevant here. OASYS is designed to help enterprises deploy and manage fleets of AI agents, the same kind of infrastructure underpinning Emily at MUSC Health. If OASYS can make complex rollouts like this easier and more reliable, it could support SoundHound’s push for larger, multi-workflow deals, which is important given the volatility that comes from relying on lumpy enterprise contracts.

Yet against this promise, investors should be aware that rising regulatory and data privacy pressures could still...

SoundHound AI's narrative projects $317.0 million revenue and $38.4 million earnings by 2029. This requires 19.9% yearly revenue growth and a $206.7 million earnings increase from -$168.3 million today.

Uncover how SoundHound AI's forecasts yield a $13.14 fair value, a 131% upside to its current price.

Exploring Other Perspectives

The most cautious analysts were already assuming only about 16 percent annual revenue growth to roughly US$287.4 million by 2029 and no near term profitability, so compared with the more optimistic view that agentic deployments like MUSC’s Emily can drive better margins and stickier contracts, you should recognize how sharply opinions diverge and consider how this new healthcare milestone might shift both narratives over time.

Explore 6 other fair value estimates on SoundHound AI - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your SoundHound AI research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free SoundHound AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SoundHound AI's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.